Cargando…
Galectin‐3 promotes CXCR2 to augment the stem‐like property of renal cell carcinoma
Although targeted therapy is usually the first‐line treatment for advanced renal cell carcinoma (RCC), some patients can experience drug resistance. Cancer stem cells are tumour‐initiating cells that play a vital role in drug resistance, metastasis and cancer relapse, while galectins (Gal) participa...
Autores principales: | Huang, Chang‐Shuo, Tang, Shye‐Jye, Lee, Mei‐Hsuan, Chang Wang, Chien‐Chih, Sun, Guang‐Huan, Sun, Kuang‐Hui |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6237593/ https://www.ncbi.nlm.nih.gov/pubmed/30246456 http://dx.doi.org/10.1111/jcmm.13860 |
Ejemplares similares
-
Galectin-3 augments tumor initiating property and tumorigenicity of lung cancer through interaction with β-catenin
por: Chung, Ling-Yen, et al.
Publicado: (2014) -
TNF‐α augments CXCR2 and CXCR3 to promote progression of renal cell carcinoma
por: Sun, Kuang‐Hui, et al.
Publicado: (2016) -
In Vivo Suppression of Autophagy via Lentiviral shRNA Targeting Atg5 Improves Lupus-Like Syndrome
por: Liu, Chi-Jui, et al.
Publicado: (2020) -
Immunotherapy for Lung Cancers
por: Ho, Ming-Yi, et al.
Publicado: (2011) -
Platinum‐based combination chemotherapy triggers cancer cell death through induction of BNIP3 and ROS, but not autophagy
por: Chung, Ling‐Yen, et al.
Publicado: (2019)